Hematology-Oncology
Latest news
269 articles · 20 / page
Reduced-Intensity Thiotepa Plus Post-Transplant Cyclophosphamide Delivers Near-Universal Engraftment and Minimal GVHD in Matched Sibling Transplantation for Adolescents and Adults With Sickle Cell Disease
A prospective multicenter study reports excellent survival, no graft failure, and very low GVHD with a thiotepa-based reduced-intensity matched sibling transplant platform for severe sickle cell disease.
Alpha-1-Antitrypsin Emerges as a Potential Salvage Option for Steroid- and Ruxolitinib-Refractory Gastrointestinal Acute GVHD
A 2026 single-center retrospective study suggests alpha-1-antitrypsin may offer favorable safety and encouraging activity in heavily pretreated gastrointestinal acute GVHD, though detailed outcome data and external validation remain essenti
MRD Does Not Consistently Predict PFS Across Modern CLL Trials: Why Surrogacy Depends on Therapy, Duration, and Sample Source
A large meta-analysis shows MRD strongly predicts outcomes for individual patients with CLL, but is an inconsistent trial-level surrogate for progression-free survival, particularly with BTK inhibitor and venetoclax-based regimens.
Adding Ipilimumab to Brentuximab Vedotin Plus Nivolumab Did Not Improve Complete Response, but May Prolong Disease Control Without Transplant in Relapsed Hodgkin Lymphoma
In randomized phase 2 E4412, BV/ipilimumab/nivolumab did not significantly improve complete response or overall PFS versus BV/nivolumab, but showed a notable signal for longer disease control among patients who did not undergo stem cell tra
Addressing the Palliative Care Gap in Adolescent and Young Adult Cancer Patients Receiving Medical Assistance in Dying
This cohort study highlights the underutilization of timely palliative care in adolescent and young adult cancer patients opting for MAID, with significant symptom burden and complex psychosocial factors influencing end-of-life decisions.
Allogeneic Stem Cell Transplantation Improves Survival in High-Risk t(6;9) AML, Especially in Younger Patients and Those Achieving CR1
A large EBMT study shows allo-HSCT provides favorable 2-year survival (65.7%) in high-risk t(6;9) AML, with superior outcomes in CR1 and pediatric/AYA patients. FLT3-ITD positivity triples relapse risk but doesn’t impact overall survival.
Baseline Circulating Tumor DNA as a Prognostic Biomarker in Untreated Follicular Lymphoma: Insights from the GALLIUM Trial
Baseline ctDNA levels predict early progression and poor survival in untreated follicular lymphoma, outperforming traditional risk scores like FLIPI. This study highlights ctDNA’s potential as a stratification tool in clinical trials.
Optimizing CML Management: Clinical Synthesis of the ASC4OPT Study and the Allosteric Inhibition Paradigm
This review synthesizes the ASC4OPT trial results alongside pivotal evidence from the ASCEMBL and ASC4FIRST studies, evaluating the role of the STAMP inhibitor asciminib in chronic myeloid leukemia across multiple treatment lines.
Donor-Derived VCAR33 CAR T-Cell Therapy Shows Promise in High-Risk AML Post-Transplant
VCAR33, a donor-derived anti-CD33 CAR T-cell therapy, demonstrated acceptable safety and preliminary efficacy in relapsed/refractory AML/MDS after allogeneic HCT, with 20% overall response rate and manageable toxicities.
Clonal Lymphocyte Expansions and JAK-STAT Mutations Drive Refractory Celiac Disease
This study uncovers clonal lymphocyte expansions and JAK-STAT pathway mutations as key drivers of refractory celiac disease, suggesting a shared pathogenic continuum between RCD1 and RCD2 while cautioning against JAK inhibitor monotherapy d
Blocking P2Y14R Emerges to Combat Venous Thromboembolism via Neutrophil-Plaque Interaction
New research identifies P2Y14R as a key regulator of neutrophil-platelet aggregates and NET formation in venous thrombosis, with proglumide showing promise as a therapeutic antagonist.
2/20/20 Model Outperforms AQUILA Criteria in Identifying High-Risk Smoldering Multiple Myeloma
The 2/20/20 risk stratification model identifies a smaller, truly high-risk SMM group with higher progression rates than the AQUILA trial criteria, suggesting better targeting for early intervention.
Revolutionizing iTTP Treatment: Reverse CAR T Cells Target Autoreactive B Cells with Precision
A groundbreaking study introduces reverse CAR T cells to selectively deplete anti-ADAMTS13 autoreactive B cells in immune-mediated thrombotic thrombocytopenic purpura (iTTP), offering a novel, precise, and potentially safer therapeutic appr
Genomic Fusion Breakpoints: A Breakthrough in Pediatric ALL MRD Monitoring
A novel genomic fusion breakpoint (GFB)-based MRD monitoring approach demonstrates superior sensitivity and specificity in pediatric ALL, addressing limitations of current IG/TCR-based methods, particularly in ETV6::RUNX1- and MEF2D-rearran
Slow but Steady: t(11;14) Myeloma Shows Superior Outcomes Despite Delayed MRD Negativity with Quadruplet Therapy
t(11;14) multiple myeloma exhibits slower MRD clearance but superior PFS with quadruplet therapy and MRD-adapted management, challenging conventional response kinetics paradigms.
Blast-Phase MPNs: One-Third Achieve Long-Term Survival with Allogeneic Transplantation
Allogeneic hematopoietic stem cell transplantation offers a potential cure for blast-phase myeloproliferative neoplasms, with one-third of patients achieving long-term survival. Key factors influencing outcomes include TP53 mutations and pe
Lenalidomide-Rituximab vs. Lenalidomide-Rituximab-Bendamustine in Relapsed/Refractory Follicular Lymphoma: A Phase II Showdown
The HOVON110/ReBeL study compares R2 and R2B regimens in R/R FL, revealing comparable efficacy but higher toxicity with bendamustine addition. Despite low CT-based CR rates, R2B showed numerically better EFS and OS.
Breaking Ferroptosis Resistance: PRMT5 Inhibition Emerges as a Game-Changer in B-Cell Lymphoma Therapy
PRMT5 inhibition sensitizes B-cell lymphomas to ferroptosis by disrupting the PRMT5-ATF5-SLC7A11 axis, offering a novel therapeutic strategy for relapsed or refractory disease.
New Statistical Model Predicts Chronic ITP in Children at Diagnosis
A novel statistical model predicts chronic immune thrombocytopenia (ITP) in children at diagnosis, using age, sex, immunoglobulin levels, and lab values, offering early clinical guidance.
Amivantamab Falls Short of Tumor Shrinkage in Recurrent or Metastatic Adenoid Cystic Carcinoma, but Disease Stabilization Was Common
In a phase 2 trial, amivantamab did not meet its primary response endpoint in recurrent/metastatic adenoid cystic carcinoma, but most patients achieved stable disease and toxicity was generally manageable.
Browse by specialty
Open language-specific specialty feeds and department pages.